Steven Cohen Cytom X Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $44.6 Billion
- Q2 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 8,084,623 shares of CTMX stock, worth $25.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
8,084,623
Previous 2,650,000
205.08%
Holding current value
$25.8 Million
Previous $1.7 Million
982.08%
% of portfolio
0.04%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CTMX
# of Institutions
88Shares Held
123MCall Options Held
305KPut Options Held
121K-
Vr Adviser, LLC New York, NY14MShares$44.6 Million6.28% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$35.3 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.38MShares$29.9 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$27 Million0.69% of portfolio
-
Commodore Capital LP New York, NY7.69MShares$24.5 Million1.63% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $210M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...